154 related articles for article (PubMed ID: 17766997)
1. Skin cancer in psoriatic arthritis treated with anti-TNF therapy.
Sheppard J; Raza K; Buckley CD
Rheumatology (Oxford); 2007 Oct; 46(10):1622-3. PubMed ID: 17766997
[No Abstract] [Full Text] [Related]
2. Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: description of 3 cases and review of the literature.
Mourão AF; Rustin M; Isenberg D
Clin Exp Rheumatol; 2010; 28(3):408-10. PubMed ID: 20576227
[TBL] [Abstract][Full Text] [Related]
3. Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register.
Coates LC; Helliwell PS
Rheumatology (Oxford); 2010 Sep; 49(9):1793-4; author reply 1794. PubMed ID: 20457729
[No Abstract] [Full Text] [Related]
4. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
5. Endometrium cancer in a female with psoriatic arthritis treated with TNF alpha antagonist adalimumab.
Erten S
Rheumatol Int; 2011 Nov; 31(11):1537-8. PubMed ID: 21120492
[No Abstract] [Full Text] [Related]
6. Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.
Peluso R; Cafaro G; Di Minno A; Iervolino S; Ambrosino P; Lupoli G; Di Minno MN
Clin Rheumatol; 2013 Jun; 32(6):743-53. PubMed ID: 23588881
[TBL] [Abstract][Full Text] [Related]
7. Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis.
Guidelli GM; Tenti S; Fioravanti A
Indian J Dermatol Venereol Leprol; 2014; 80(2):187-9. PubMed ID: 24685874
[No Abstract] [Full Text] [Related]
8. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy.
Izzi S; Francesconi F; Visca P; Altieri A; De Mutiis C; Trevisan G; Bonifati C
Dermatol Online J; 2010 May; 16(5):16. PubMed ID: 20492833
[TBL] [Abstract][Full Text] [Related]
9. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
10. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study.
Costa L; Caso F; Del Puente A; Di Minno MN; Peluso R; Scarpa R
J Rheumatol; 2016 Dec; 43(12):2149-2154. PubMed ID: 27633825
[TBL] [Abstract][Full Text] [Related]
12. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
Coates LC; Tillett W; Chandler D; Helliwell PS; Korendowych E; Kyle S; McInnes IB; Oliver S; Ormerod A; Smith C; Symmons D; Waldron N; McHugh NJ;
Rheumatology (Oxford); 2013 Oct; 52(10):1754-7. PubMed ID: 23887065
[No Abstract] [Full Text] [Related]
13. Optic neuritis in a psoriatic arthritis patient treated by infliximab.
Minami-Hori M; Tsuji H; Takahashi H; Hanada K; Iizuka H
J Dermatol; 2013 Apr; 40(4):298-9. PubMed ID: 23289758
[No Abstract] [Full Text] [Related]
14. Erythema nodosum, a "red flag" during anti-TNF therapy.
Dalmau-Carolà J
Int J Rheum Dis; 2013 Aug; 16(4):493-4. PubMed ID: 23992277
[No Abstract] [Full Text] [Related]
15. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.
Palazzi C; D'Angelo S; Leccese P; Padula A; Olivieri I
Expert Opin Drug Saf; 2014 Feb; 13(2):191-6. PubMed ID: 24219428
[TBL] [Abstract][Full Text] [Related]
16. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis after anti-TNF therapy: a continuous learning process.
Psichogiou M; Sfikakis PP; Kontos F; Daikos GL
Scand J Rheumatol; 2012 Oct; 41(5):401-3. PubMed ID: 22803620
[No Abstract] [Full Text] [Related]
18. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.
Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P
Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559
[No Abstract] [Full Text] [Related]
19. Tumor necrosis factor inhibitors continuation rates in patients with psoriatic arthritis: A French retrospective monocentre study.
Rio S; Vincent FB; Michel M; Cesini J; Marcelli C
Joint Bone Spine; 2015 Oct; 82(5):377-8. PubMed ID: 25677408
[No Abstract] [Full Text] [Related]
20. Evaluating the real-world benefits and risks of anti-tumor necrosis factor therapies.
Low A; Hyrich K
J Rheumatol; 2013 Jan; 40(1):4-6. PubMed ID: 23280161
[No Abstract] [Full Text] [Related]
[Next] [New Search]
